PURPOSE: To evaluate the safety and preliminary efficacy of intravitreal ranibizumab for nonneovascular idiopathic macular telangiectasia Type 2. METHODS: Single-center, open-label Phase II clinical trial enrolling five participants with bilateral nonneovascular idiopathic macular telangiectasia Type 2. Intravitreal ranibizumab (0.5 mg) was administered every 4 weeks in the study eye for 12 months with the contralateral eye observed. Outcome measures included changes in best-corrected visual acuity, area of late-phase leakage on fluorescein angiography, and retinal thickness on optical coherence tomography. RESULTS: The study treatment was well tolerated and associated with few adverse events. Change in best-corrected visual acuity at 12 months was not significantly different between treated study eyes (0.0 ± 7.5 letters) and control fellow eyes (+2.2 ± 1.9 letters). However, decreases in the area of late-phase fluorescein angiography leakage (-33 ± 20% for study eyes, +1 ± 8% for fellow eyes) and in optical coherence tomography central subfield retinal thickness (-11.7 ± 7.0% for study eyes and -2.9 ± 3.5% for fellow eyes) were greater in study eyes compared with fellow eyes. CONCLUSION: Despite significant anatomical responses to treatment, functional improvement in visual acuity was not detected. Intravitreal ranibizumab administered monthly over a time course of 12 months is unlikely to provide a general and significant benefit to patients with nonneovascular idiopathic macular telangiectasia Type 2.
RCT Entities:
PURPOSE: To evaluate the safety and preliminary efficacy of intravitreal ranibizumab for nonneovascular idiopathic macular telangiectasia Type 2. METHODS: Single-center, open-label Phase II clinical trial enrolling five participants with bilateral nonneovascular idiopathic macular telangiectasia Type 2. Intravitreal ranibizumab (0.5 mg) was administered every 4 weeks in the study eye for 12 months with the contralateral eye observed. Outcome measures included changes in best-corrected visual acuity, area of late-phase leakage on fluorescein angiography, and retinal thickness on optical coherence tomography. RESULTS: The study treatment was well tolerated and associated with few adverse events. Change in best-corrected visual acuity at 12 months was not significantly different between treated study eyes (0.0 ± 7.5 letters) and control fellow eyes (+2.2 ± 1.9 letters). However, decreases in the area of late-phase fluorescein angiography leakage (-33 ± 20% for study eyes, +1 ± 8% for fellow eyes) and in optical coherence tomography central subfield retinal thickness (-11.7 ± 7.0% for study eyes and -2.9 ± 3.5% for fellow eyes) were greater in study eyes compared with fellow eyes. CONCLUSION: Despite significant anatomical responses to treatment, functional improvement in visual acuity was not detected. Intravitreal ranibizumab administered monthly over a time course of 12 months is unlikely to provide a general and significant benefit to patients with nonneovascular idiopathic macular telangiectasia Type 2.
Authors: Robert C Watzke; Michael L Klein; James C Folk; Samuel G Farmer; Richard S Munsen; Robert J Champfer; K R Sletten Journal: Retina Date: 2005-09 Impact factor: 4.256
Authors: G Matt; S Sacu; C Ahlers; C Schütze; R Dunavoelgyi; F Prager; C Pruente; U Schmidt-Erfurth Journal: Eye (Lond) Date: 2010-09-24 Impact factor: 3.775
Authors: Robert P Finger; Peter Charbel Issa; Rolf Fimmers; Frank G Holz; Gary S Rubin; Hendrik P N Scholl Journal: Invest Ophthalmol Vis Sci Date: 2008-11-07 Impact factor: 4.799
Authors: Wai T Wong; Farzin Forooghian; Zigurts Majumdar; Robert F Bonner; Denise Cunningham; Emily Y Chew Journal: Am J Ophthalmol Date: 2009-07-02 Impact factor: 5.258
Authors: Traci E Clemons; Marc C Gillies; Emily Y Chew; Alan C Bird; Tunde Peto; Maria J Figueroa; Molly W Harrington Journal: Ophthalmic Epidemiol Date: 2010 Jan-Feb Impact factor: 1.648
Authors: Magali Saint-Geniez; Arindel S R Maharaj; Tony E Walshe; Budd A Tucker; Eiichi Sekiyama; Tomoki Kurihara; Diane C Darland; Michael J Young; Patricia A D'Amore Journal: PLoS One Date: 2008-11-03 Impact factor: 3.240
Authors: Tunde Peto; Tjebo F C Heeren; Traci E Clemons; Ferenc B Sallo; Irene Leung; Emily Y Chew; Alan C Bird Journal: Retina Date: 2018-01 Impact factor: 4.256
Authors: Emily Y Chew; Traci E Clemons; Tunde Peto; Ferenc B Sallo; Avner Ingerman; Weng Tao; Lawrence Singerman; Steven D Schwartz; Neal S Peachey; Alan C Bird Journal: Am J Ophthalmol Date: 2014-12-19 Impact factor: 5.258
Authors: Peter Charbel Issa; Mark C Gillies; Emily Y Chew; Alan C Bird; Tjebo F C Heeren; Tunde Peto; Frank G Holz; Hendrik P N Scholl Journal: Prog Retin Eye Res Date: 2012-12-03 Impact factor: 21.198
Authors: Qinqin Zhang; Ruikang K Wang; Chieh-Li Chen; Andrew D Legarreta; Mary K Durbin; Lin An; Utkarsh Sharma; Paul F Stetson; John E Legarreta; Luiz Roisman; Giovanni Gregori; Philip J Rosenfeld Journal: Retina Date: 2015-11 Impact factor: 4.256
Authors: Eric J Sigler; John C Randolph; Jorge I Calzada; Steve Charles Journal: Graefes Arch Clin Exp Ophthalmol Date: 2012-09-06 Impact factor: 3.117